Otcqb Podcast
BioVie Inc.
- Autor: Vários
- Narrador: Vários
- Editora: Podcast
- Duração: 0:04:41
- Mais informações
Informações:
Sinopse
100,000 patients in the U.S. have ascites due to advanced liver cirrhosis, with no approved drug to treat ascites. Jonathan Adams, CEO & CFO of BioVie Inc. (OTCQB: BIVI) discusses how the company is developing what they hope to be the first ever approved drug to treat ascites.
